High-sensitivity C-reactive protein is independently associated with arterial stiffness in women with metabolic syndrome

Journal of Cardiovascular Nursing

Volumn 27, Issue 1, 2012, Pages 61-67

  Oh, Eui Geum ^a   Kim, Soo Hyun ^b   Bang, So Youn ^c   Hyun, Sa Saeng ^d   Im, Jee Aee ^e   Lee, Jung Eun ^a   Yoo, Jae Yong ^a  

^a Yonsei University   (South Korea)

^b Inha University   (South Korea)

^c Youngdong University   (South Korea)

^d Galsan Community Health Center   (South Korea)

^e INTOTO Inc   (South Korea)

Author keywords

adiponectin; arterial stiffness; C reactive protein; metabolic syndrome

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN;

ARTERIAL STIFFNESS; ARTICLE; BLOOD; FEMALE; HUMAN; METABOLIC SYNDROME X; MIDDLE AGED; PATHOPHYSIOLOGY;

ADIPONECTIN; C-REACTIVE PROTEIN; FEMALE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; VASCULAR STIFFNESS;

EID: 84855960917     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0b013e31820e5a91     Document Type: Article

References (52)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev. 2005;13(6):322-327.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health andNutrition Examination Survey. JAMA. 2002;287(3): 356-359. (Pubitemid 34251969)
4. Nishida M, Moriyama T, Ishii K, et al. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin Chim Acta. 2007;384(1-2):99-104. (Pubitemid 47248651)
5. FestaA,D'Agostino RJr,HowardG,Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-47. (Pubitemid 30430551)
6. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110(4):380-385. (Pubitemid 38993845)
7. Yun JE, Kimm H, Jo J, Jee SH. Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations. Metabolism. 2010;59(3):424-429.
8. ParkHT, Cho SH, ChoGJ, et al. Relationship between serum adipocytokine levels and metabolic syndrome in menopausal women. Gynecol Endocrinol. 2009;25(1):27-31.
9. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008;57(4):494-501. (Pubitemid 351317963)
10. Gilardini L, McTernan PG, Girola A, et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis. 2006;189(2):401-407. (Pubitemid 44634487)
11. Abdullah AR, Hasan HA, Raigangar VL. Analysis of the relationship of leptin, high-sensitivity C-reactive protein, adiponectin, insulin, and uric acid to metabolic syndrome in lean, overweight, and obese young females.Metab Syndr Relat Disord. 2009;7(1):17-22.
12. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond). 2006;110(3):267-278. (Pubitemid 43341630)
13. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-689. (Pubitemid 32893993)
14. LeeWL, LeeWJ, Chen YT, et al. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. Metabolism. 2006;55(8):1029-1034.
15. Okosun IS. Metabolic syndrome and C-reactive protein in American adults: the impact of abdominal obesity. Metab Syndr Relat Disord. 2008;6(4):289-297.
16. Ahonen T, Saltevo J, LaaksoM, Kautiainen H, Kumpusalo E, Vanhala M. Gender differences relating to metabolic syndrome and proinflammation in Finnish subjects with elevated blood pressure. Mediators Inflamm. 2009. http://www.ncbi.nlm.nlm.nih.gov/pmc/articles/PMC2730476/?tool=pubmed. DOI: 10.1155/2009/959281.
17. Lai MM, Li CI, Kardia SL, et al. Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population. BMC Public Health. 2010;10(1):429.
18. Ridker PM, Buring JE,Cook NR,Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-397.
19. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. (Pubitemid 36158056)
20. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation. 2004;109(16): 1955-1959. (Pubitemid 38544485)
21. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85-89. (Pubitemid 36091630)
22. Schuur M, Henneman P, van Swieten JC, et al. Insulinresistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur J Epidemiol. 2010;25(8):561-568.
23. King GA, Deemer SE, Thompson DL. Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women. Acta Diabetol. 2010;Online published
24. Salvi P, Safar ME, Labat C, Borghi C, Lacolley P, Benetos A. Heart disease and changes in pulse wave velocity and pulse pressure amplification in the elderly over 80 years: the PARTAGE Study. J Hypertens. 2010;28(10):2127- 2133.
25. Gomez-Marcos MA, Recio-Rodriguez JI, Rodriguez-Sanchez E, et al. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol. BMC Public Health. 2010;18(10):143.
26. Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis. J Clin Endocrinol Metab. 2009;94(8):2893-2899.
27. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, RimmEB. Inflammation, themetabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis. 2008;197(1):392-399. (Pubitemid 351273261)
28. Lakoski SG, Cushman M, Criqui M, et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152(3): 593-598. (Pubitemid 44233418)
29. Lin HF, Liu CK, Liao YC, Lin RT, Chen CS, Juo SH. The risk of the metabolic syndrome on carotid thickness and stiffness: sex and age specific effects. Atherosclerosis. 2010;210(1): 155-159.
30. Oh EG, Bang SY, Hyun SS, et al. Effects of a 6-month lifestyle modification intervention on the cardiometabolic risk factors and health-related qualities of life in womenwith metabolic syndrome. Metabolism. 2010;59(7):1035-1043.
31. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. (Pubitemid 41532612)
32. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the national cholesterol education program adult treatment panel definition of the metabolic syndrome to Asians. Diabetes Care. 2004;27:1182-1186. (Pubitemid 38579787)
33. Ohnishi H, Saitoh S, Takagi S, et al. Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care. 2003;26(2): 437-440. (Pubitemid 36929069)
34. Sung SH, Chuang SY, SheuWH, Lee WJ, Chou P, Chen CH. Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal proYB-type natriuretic peptide in the general population. Am J Cardiol. 2009;103(10):1411-1416.
35. Nagano M, Nakamura M, Sato K, Tanaka F, Segawa T, Hiramori K. Association between serum C-reactive protein levels and pulse wave velocity: a population-based crosssectional study in a general population. Atherosclerosis. 2005; 180(1):189-195.
36. KomatsuM, Ohfusa H, Aizawa T, Hashizume K. Adiponectin inversely correlates with high sensitive C-reactive protein and triglycerides, but not with insulin sensitivity, in apparently healthy Japanese men. Endocr J. 2007;54(4):553-558. (Pubitemid 47414602)
37. Nam JS, Park JS, Cho MH, et al. The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose: cardiovascular risks and adiponectin in IFG. Diabetes Res Clin Pract. 2009;84(2):145-151.
38. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens. 2005;18(12 pt 1):1543-1548. (Pubitemid 41814674)
39. Koh SB, Park JK, Yoon JH, et al. Preliminary report: a serious link between adiponectin levels and metabolic syndrome in a Korean nondiabetic population. Metabolism. 2010;59(3): 333-337.
40. Yu RH, Ho SC, Lam CW, Woo JL, Ho SS. Distribution of C-reactive protein and its association with subclinical atherosclerosis in asymptomatic postmenopausal Chinese women. Metabolism. 2010;59(11):1672-1679.
41. Kim YK. Impact of the metabolic syndrome and its components on pulse wave velocity. Korean J Intern Med. 2006; 21(2):109-115.
42. Roes SD, Alizadeh Dehnavi R, Westenberg JJ, et al. Assessment of aortic pulse wave velocity and cardiac diastolic function in subjects with and without the metabolic syndrome: HDL cholesterol is independently associated with cardiovascular function. Diabetes Care. 2008;31(7):1442-1444.
43. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens. 2002;15(4 pt 1):321-325. (Pubitemid 34408971)
44. Takeda T, Hoshida S,Nishino M, Tanouchi J,Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis. 2003;169(1):155-158. (Pubitemid 36830934)
45. AlbertMA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol. 2004;93(10):1238-1242. (Pubitemid 38595677)
46. Matthews KA, SowersMF, Derby CA, et al. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study ofWomen's Health Across the Nation (SWAN). Am Heart J. 2005;149(6):1066-1073. (Pubitemid 40848152)
47. Mattace-Raso FU, van der Cammen TJ, van der Meer IM, et al. C-reactive protein and arterial stiffness in older adults: the Rotterdam Study. Atherosclerosis. 2004;176(1):111-116. (Pubitemid 39078652)
48. Kullo IJ, Seward JB, Bailey KR, et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens. 2005; 18(8):1123-1129. (Pubitemid 41139913)
49. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR,Wilkinson IC. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol. 2004;24(5):969-974. (Pubitemid 38620880)
50. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106(12):1439-1441.
51. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102(18):2165- 2168.
52. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerosis drugs. Circulation. 2001;103(21):2531-2534 (Pubitemid 32521959)